These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 36922354

  • 1. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM, Pawlik TM.
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [Abstract] [Full Text] [Related]

  • 2. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G, Mahipal A, John BV.
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
    Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM.
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
    [Abstract] [Full Text] [Related]

  • 8. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A, Ricci AD, Brandi G.
    Cancer Treat Res Commun; 2021 May; 27():100356. PubMed ID: 33799004
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G.
    J Hepatol; 2020 Feb; 72(2):364-377. PubMed ID: 31954498
    [Abstract] [Full Text] [Related]

  • 11. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L.
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI, Gores GJ.
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
    Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME.
    CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P.
    Cochrane Database Syst Rev; 2021 Sep 13; 9(9):CD012814. PubMed ID: 34515993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.